Singapore: Gobal contract manufacturing firm, FUJIFILM Diosynth Biotechnologies, has expanded its cell culture manufacturing capabilities with the addition of two 2000L single-use bioreactors installed in the company's site in US and UK.

The new reactors will complement the range of vessels, adding further flexibility for customer requirements.

"The addition of these two new bioreactors will meet the demand we are seeing for a 2000L platform, and offer a cost-effective, low-risk route to market through 'scaling-out' from early phase to commercial manufacture," said Mr Steve Bagshaw, chief executive officer, FUJIFILM Diosynth Biotechnologies.

He added, "Being similar to our existing bioreactors means they will fit seamlessly into our facilities. Having identical single-use operations on both sides of the Atlantic offers our customers flexibility and easy access to global markets. Combined with the expertise of our process development scientists to produce high-titer cell lines, our focus on single-use bioreactor technology for cell culture processes is world class."

FUIJIFILM has been using single-use technologies in the last three years and are inspected by key regulatory authorities and utilize both traditional platforms as well as the latest single-use technologies. The new 2000L bioreactors are expected to be operational by November 2014 in US and in UK in January 2015.

Mr Bagshaw concluded, "With these expansions, FUJIFILM Diosynth Biotechnologies is able to deliver a significantly enhanced, full life cycle 'Gene to GMP' service for our customers."